Alembic Pharma completes USFDA inspection at Vadodara facility

Alembic Pharmaceuticals (BSE:APLLTD) announced today that the United States Food and Drug Administration (USFDA) has completed an inspection of its Bioequivalence Facility located in Vadodara. The inspection took place from March 3rd to March 7th, 2025, and was a scheduled event. The USFDA issued a Form 483 with one procedural observation. Alembic Pharmaceuticals stated that it will provide a comprehensive response to the USFDA regarding the observation within the stipulated timeframe. The company reaffirms its commitment to upholding the highest quality standards and compliance at all times. This announcement was made to the National Stock Exchange of India Ltd.